We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Myval THV Demonstrates 1-Year Noninferiority to Established Transcatheter Heart Valves: Insights from the LANDMARK Trial

MedXY Editorial Team•Dec 25, 2025•Cardiology
aortic stenosisTAVR

The Evolution of TAVR and the Quest for Versatility

Since the inception of transcatheter aortic valve replacement (TAVR), the landscape has been dominated by a few established platforms, primarily the balloon-expandable SAPIEN series and the self-expanding Evolut series. While these devices have revolutionized the treatment of symptomatic severe aortic stenosis, particularly in high-risk and elderly populations, the search for next-generation valves that offer greater sizing precision and comparable long-term efficacy continues. The LANDMARK trial represents a pivotal moment in this evolution, evaluating the Myval balloon-expandable transcatheter heart valve (THV) series against these established contemporary standards.

Highlights

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Aspirin Use, Lipoprotein(a), and Calcific Aortic Valve Disease: Insights from the Multi-Ethnic Study of AtherosclerosisThis review synthesizes evidence linking aspirin use to reduced risk of calcific aortic valve disease in persons with elevated lipoprotein(a), highlighting the potential for targeted preventive strategies.Sep 11, 2026Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: Evidence and Insights from the NOTION-4 TrialThe NOTION-4 trial demonstrates that 3 months of DOAC therapy post-TAVR reduces early HALT incidence compared to SAPT, but benefits diminish after discontinuation, highlighting nuanced balance between thrombosis prevention and bleeding riskSep 1, 2026Revolutionizing Aortic Stenosis Screening: AI-Enabled Focused Cardiac Ultrasound with Novice OperatorsA novel deep learning algorithm accurately detects moderate or greater aortic stenosis using AI-guided focused cardiac ultrasound acquired by novice operators, presenting a scalable solution to expand screening accessibility.Aug 29, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Seven-Year Health Outcomes After TAVR Versus SAVR in Low-Risk Aortic Stenosis Patients: Insights from the PARTNER 3 Trial
In low-risk severe aortic stenosis patients, both TAVR and SAVR provide sustained health status improvements over seven years, with TAVR offering faster early recovery but similar long-term health outcomes.
Aug 18, 2026
Treadmill Stress Test Identifies Symptoms in 15% of Asymptomatic Severe Aortic Stenosis Patients, but One in Five Remain Untreated at One YearIn the EARLY TAVR registry, treadmill stress testing was safe and unmasked symptoms in 15% of asymptomatic severe aortic stenosis patients. Yet 20% of those with an indication for prompt aortic valve replacement remained untreated after one year.Jul 28, 2026
Seven-Year Valve Durability Outcomes Comparing Transcatheter and Surgical Aortic Valve Replacement: Insights from the PARTNER 3 Randomized TrialAn evidence-based review of the 7-year durability of transcatheter versus surgical aortic bioprosthetic valves in low-risk severe aortic stenosis patients, highlighting comparable long-term structural performance and need for reinterventionJun 24, 2026